- Book
- December 2022
- 464 Pages
- Book
- April 2022
- 480 Pages
- Book
- December 2021
- 624 Pages
- Book
- April 2021
- 6032 Pages
€4059EUR$4,586USD£3,333GBP
- Book
- August 2020
- 432 Pages
- Book
- November 2019
- 368 Pages
- Book
- October 2019
- 472 Pages
- Book
- September 2019
- 272 Pages
- Book
- April 2019
- 384 Pages
- Book
- August 2018
- 816 Pages
- Book
- April 2018
- 472 Pages
- Book
- January 2018
- 536 Pages
- Book
- January 2016
- 472 Pages
- Book
- March 2015
- 256 Pages
- Book
- July 2012
- 542 Pages
- Book
- June 2012
- 412 Pages
- Book
- April 2012
- 268 Pages
- Book
- October 2009
- 912 Pages

Prodrugs are a type of biotechnology that involves the modification of a drug molecule to improve its pharmacokinetic properties. This is done by making the drug more soluble, increasing its absorption, or making it more stable in the body. Prodrugs are designed to be more effective and safer than the original drug, and can be used to treat a variety of diseases.
Prodrugs are used in a variety of therapeutic areas, including cancer, cardiovascular disease, and infectious diseases. They are also used to improve the delivery of drugs to specific tissues or organs, and to reduce the side effects of drugs.
The prodrug market is growing rapidly, driven by the increasing demand for more effective and safer drugs. The market is expected to continue to grow in the coming years, as more companies develop and launch new prodrugs.
Some companies in the prodrug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more